Estados Unidos · Bolsa y Finanzas · Investor's Business Daily

Uniqure Plummets 37% On Another Shocking Twist For Its Huntington's Drug

Publicado por Investor's Business Daily · Estados Unidos hace 1 d

Uniqure stock crashed Tuesday on a disappointing four-year update for its gene therapy in patients with Huntington's disease.

Leer el artículo completo en Investor's Business Daily Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.investors.com)

También te puede interesar

Achieve a new Buy at Stifel on potential of smoking cessation drug cytisinicline

E.E.O.C. Sues Harvard for Data on Diversity in Hiring Practices

Business Insider

15 US colleges now cost more than $100,000 a year. See the list, ranked by cost of attendance.

Trump's meeting with tech leaders leaves AI safety more unsettled than ever

Open USD takes on Tether, Circle with a different stablecoin model that's 'building money'

The 'Gen Z stare' is telling us something important about today's economy